摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[Pd(μ-Cl)(3-(CHO)C6H3CH=NCy)]2 | 174865-79-3

中文名称
——
中文别名
——
英文名称
[Pd(μ-Cl)(3-(CHO)C6H3CH=NCy)]2
英文别名
chloropalladium(1+);3-(cyclohexyliminomethyl)benzene-4-ide-1-carbaldehyde
[Pd(μ-Cl)(3-(CHO)C6H3CH=NCy)]2化学式
CAS
174865-79-3
化学式
C28H32Cl2N2O2Pd2
mdl
——
分子量
712.32
InChiKey
BFSHYRKGMKAOQL-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    None
  • 重原子数:
    None
  • 可旋转键数:
    None
  • 环数:
    None
  • sp3杂化的碳原子比例:
    None
  • 拓扑面积:
    None
  • 氢给体数:
    None
  • 氢受体数:
    None

反应信息

  • 作为反应物:
    参考文献:
    名称:
    钯(II)的官能化环金属化配合物的反应性。[Pd {3-(CHO)C 6 H 3 C(H)NCy}(Br)(PEtPh 2)的晶体和分子结构
    摘要:
    环金属化配合物[{Pd [3-(CHO)C 6 H 3 C(H)NCy}(X)} 2 ]的处理[X = Cl(1),Br(2),I(3)]配合物/膦摩尔比为1:2或1:4的叔单膦化合物提供了卤化物桥接的裂解[Pd {3-(CHO)C 6 H 3 C(H)NCy}(X)(L)](6 – 17)和非环金属化的配合物[Pd {3-(CHO)C 6 H 3 C(H)NCy}(X)(L)2 ](18 – 23)(X = Cl,Br或I; L = PPH 3,PEtPh 2,PET 2 PH或PMePh2)。的反应6 - 17 1或1:1:2的摩尔比,得到[钯{3-(CYC(H)N)C与环己1在复杂/胺6 ħ 3 C(H)NCy}(X)( L)](24 – 28)和非环金属化的[Pd {3-(CyC(H)N)C 6 H 3 C(H)NCy}(X)(L)(NH 2 Cy)](29 – 32
    DOI:
    10.1016/s0022-328x(97)00687-6
  • 作为产物:
    描述:
    [Pd(mu.-OAc)(3-(CHO)C6H3CH=NCy)]2 、 sodium chloride 以 丙酮 为溶剂, 以87%的产率得到[Pd(μ-Cl)(3-(CHO)C6H3CH=NCy)]2
    参考文献:
    名称:
    Synthesis and characterization of cyclometallated complexes of palladium(II) and manganese(I) with bidentate Schiff bases
    摘要:
    Treatment of N,N-isophthalylidenebis(cyclohexylamine) 1,3-(CyN=CH)(2)C6H4(L(2)) (Cy = cyclohexyl) with palladium(II) acetate in glacial acetic acid gave after column chromatography the monocyclometallated dimer complex [{Pd[3-(CHO)C6H3C(H)=NCy][O(2)CMe)}(2)] (1) with a free formyl group on each phenyl ring, and a mixture of 1 with the doubly cyclometallated complex [Pd(3-(CyN=CH)C6H3C(H)=NCy)(O(2)CMe)] (2). Treatment of 1 with cyclohexylamine gave the corresponding dimer complex [{Pd[3-(CyN=CH)C6H3C(H)=NCy](O(2)CMe)}(2)] (17) with an uncoordinated C=N group on each phenyl ring. Treatment of 1 and 2 with aqueous NaX gave the dimer complexes [{Pd[3-(CHO)C6H3C(H)=NCy]{(X)}(2)] (3: X = Cl; 4: X = Br; 5: X = I) and a mixture of 3, 4 or 5 with the doubly cyclometallated complex [Pd[3-(CyN=CH)C6H3O(H)=NCy](X)] (6: X = Cl; 7: X = Br; 8: X = I), respectively. The dicydometallated iodo complex 8 was isolated pure. Treatment of 3, 4 or 5 with cyclohexylamine in a 1:2 or 1:4 molar ratio gave the cyclometallated complexes [Pd[3-(CHO)C6H3C(H)=NCy](X)(NH(2)Cy)] (9: X = Cl; 10: X = Br; 11: x = I) and [Pd[3-(CyN=CH)C6H3O(H)=NCy](X)(NH(2)Cy)] (12: X = Cl; 13: X = Br; 14: X = I), respectively; the last three compounds 6 each contain an uncoordinated C=N group. The corresponding bromo and iodo analogues were made similarly. Treatment of 3, 4 or 5 with thallium cyclopentadienyl or thallium acetylacetonate gave the mononuclear complexes [Pd[3-(CHO)C6H3C(H)=NCy)(C5H5)] (15) and [Pd{3-(CHO)C6H3C(H)=NCy)(H3CCOCHCOCH3)] (16), respectively. Treatment of L(2) with MnMe(CO)(5) in a 1.1 molar ratio gave the monocyclometallated complex [(OC)(4)Mn{3-(CHO)C6H3C(H)=NCy}] (18) by cleavage of one C=N bond, whereas treatment of L(2) with MnMe(CO)(5) in a 1:1.2 molar ratio produced a mixture of the doubly cyclometallated complex 19 and the monocyclometallated complex 20 without cleavage of the C=N bond. Treatment of N,N-terephthalylidenebis(cyclohexylamine), 1,4-(CyN=CH)(2)C6H4(L(1)) (Cy = cyclohexyl), with MnMe(CO)(5) in a 1:1.2 molar ratio gave a mixture of the monocyclometallated compound [(OC)(4)Mn{4-(CHO)C6H3C(H)=NCy}] (22) and the monocyclometallated compound [(OC)(4)Mn{4-(CyN=CH)C6H3C(H)=NCy}] (23); compound 22 was isolated in a pure state.
    DOI:
    10.1016/0022-328x(95)05691-h
点击查看最新优质反应信息

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫